Response to comments from the International Patient Organization for Primary Immunodeficiencies on ‘Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries’-Reference-Cited by-同舟云学术

Response to comments from the International Patient Organization for Primary Immunodeficiencies on ‘Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries’

Published:2024-06-18 Issue:9 Volume:119 Page:1023-1024
ISSN:0042-9007
Container-title:Vox Sanguinis
language:en
Short-container-title:Vox Sanguinis

Author:

Burnouf Thierry¹²^ORCID,Epstein Jay³,Faber Jean‐Claude⁴,Smid W. Martin⁵^ORCID

Affiliation:

1. Graduate Institute of Biomedical Materials and Tissue Engineering College of Biomedical Engineering, Taipei Medical University Taipei Taiwan

2. International PhD Program in Biomedical Engineering College of Biomedical Engineering, Taipei Medical University Taipei Taiwan

3. McLean Virginia USA

4. Association Luxembourgeoise des Hémophiles Luxembourg City Luxembourg

5. Sanquin Consulting Services Amsterdam and Academic Institute IDTM Groningen The Netherlands

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/vox.13695

Reference8 articles.

1. A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia

2. Nanofiltration of plasma-derived biopharmaceutical products

3. World Health Organization.Medical Product Alert N°3/2022: Falsified Intratect (human normal immunoglobulin). Falsified Intratect (human normal immunoglobulin) identified in the WHO Regions of the Americas Eastern Mediterranean and South‐East Asia. Available from:https://www.who.int/news/item/27-05-2022-medical-product-alert-n-3-2022-falsified-intratect-human-normal-immunoglobulin. Last accessed 21 May 2024.

4. Intravenous Immunoglobulin G (IVIG) Need Assessment Survey Toward Local Manufacturing of IVIG Using a Mini-Pool Plasma Fractionation Technique

5. Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII